Alamandine|cas:1176306-10-7|西域试剂

Alamandine,98.95%

产品编号：Bellancom-P3108| CAS NO：1176306-10-7| 分子式：C₄₀H₆₂N₁₂O₉| 分子量：855.00

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P3108		￥3800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Alamandine

产品介绍

Alamandine 是一种血管活性肽，是肾素-血管紧张素系统 (RAS) 的成员，还是一种 G 蛋白偶联受体 MrgD 的内源性配体。Alamandine 可通过抗高血压作用来保护肾脏和心脏。

生物活性

Alamandine, a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. Alamandine targets to protect the kidney and heart through anti-hypertensive actions.

体外研究

Alamandine is generated by catalysis of Ang A via ACE2 or directly from Angiotensin 1-7 (Ang-(1-7)). Derived from angiotensin II (Ang II) by Ang II-converting enzyme 2 (ACE2), it shows vasodilating (thus protective) properties. Ang (1-7) can be decarboxylated to a peptide called Alamandine. Alamandine is also an endogenous peptide identified in human blood.
Alamandine elevates cAMP concentration in primary endothelial and mesangial cells, also suggesting Gs coupling.
Alamandine decreases secretion, expression, and blood levels of leptin. Alamandine induced expression of iNOS and plasminogen activator inhibitor-1 (PAI-1) in adipose tissue and isolated adipocytes.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Alamandine (0.15 μL/h; administered by mini-osmotic pumps; for 6 weeks) treatment ameliorates hypertension and impaires left ventricle (LV) function in SHRs. Also decreases the mass gains of heart and lung in SHRs, suppresses cardiomyocyte cross-sectional area expansion, and inhibits the mRNA levels of atrial natriuretic peptide and brain natriuretic peptide.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male spontaneously hypertensive rats (SHRs, 50-week-old)
Dosage:	0.15 μL/h (~50 μg/kg/day)
Administration:	Administered by mini-osmotic pumps; for 6 weeks
Result:	Attenuated hypertension, alleviated cardiac hypertrophy, and improved LV function.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male spontaneously hypertensive rats (SHRs, 50-week-old)
Dosage:	0.15 μL/h (~50 μg/kg/day)
Administration:	Administered by mini-osmotic pumps; for 6 weeks
Result:	Attenuated hypertension, alleviated cardiac hypertrophy, and improved LV function.

性状

Solid

溶解性数据

In Vitro:

H₂O : 25 mg/mL (29.24 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.1696 mL	5.8480 mL	11.6959 mL
5 mM	0.2339 mL	1.1696 mL	2.3392 mL
10 mM	0.1170 mL	0.5848 mL	1.1696 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶